TQB 3824
Alternative Names: TQB-3824Latest Information Update: 06 Sep 2021
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action CDC7 protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Sep 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) in September 2021 (NCT05028218)
- 10 Apr 2021 Pharmacodynamics data from an in-vitro trial in Solid tumors presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 10 Apr 2021 Preclinical trials in Solid tumours in China (PO) as of April 2021